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Abstract: Severe asthma is an important topic in respiratory diseases, due to its high impact on
morbidity and mortality as well as on health-care resources. The many challenges that still exist in
the management of the most difficult-to-treat forms of the disease, and the acknowledgement of
the existence of unexplored areas in the pathophysiological mechanisms and the therapeutic targets
represent an opportunity to gather experts in the field with the immediate goals to summarize current
understanding about the natural history of severe asthma and to identify gaps in knowledge and
research opportunities, with the aim to contribute to improved medical care and health outcomes.
This article is a consensus document from the “International Course on Severe Asthma” that took
place in Palermo, Italy, on May 10–11, 2019. Emerging topics in severe asthma were addressed and
discussed among experts, with special focus on patient’s needs and research opportunities, with the
aim to highlight the unanswered questions in the diagnostic process and therapeutic approach.
Keywords: severe asthma; precision medicine; biomarkers; patient’s perspective
1. Introduction
Severe asthma can be limiting for patients and frustrating for clinicians. Patients suffering from
the most severe forms of the disease have the greatest impairment in their quality of life and generate
the highest medical and societal costs. On the other hand, clinicians face difficult to treat symptoms
and concomitant conditions that negatively influence the natural course of the disease. In this context,
experts in the field gathered in Palermo, Italy, to participate in the “International Course on Severe
Asthma” on May 10–11, 2019. Course participants represented expertise in asthma, pulmonology,
allergy/immunology and emergency medicine and discussed emerging topics in severe asthma, with
a special focus on unmet needs in education and research. The choice of the topics was based on a
Delphi consensus that was conducted among general practitioners and pulmonologists in the area of
Palermo in the year preceding the course, and those that were selected are summarized in Table 1. The
urgency for the meeting came from the need of a consensus on the definition of severe asthma. In 1999,
the European Respiratory Society (ERS) defined difficult to treat and severe asthma as “asthma, poorly
controlled in terms of chronic symptoms, with episodic exacerbations, persistent and variable airway
obstruction and continued requirement for short-acting beta-2-agonists and a reasonable dose of inhaled
corticosteroids” [1]. Since then, the definition has evolved: in 2000, the American Thoracic Society (ATS)
defined refractory asthma on the basis of two major criteria—1. treatment with oral corticosteroids >
50% of the time, or 2 high doses of inhaled corticosteroids (>1200 µg beclomethasone equivalent)—and
at least two minor criteria, including requirement for daily treatment with short-acting beta-2-agonists
(SABA), theophylline or leukotriene-receptor antagonist (LTRA), daily asthma symptoms requiring
rescue medication, persistent airway obstruction; diurnal peak expiratory flow (PEF) variability > 20%,
one or more urgent care visits for asthma per year, three or more oral steroid bursts per year, prompt
deterioration with > 25% reduction in oral or inhaled corticosteroids (ICS) dosing and/or near fatal
asthma event in the past [2]. This definition was applicable only when other conditions had been
excluded, exacerbating factors optimally treated and poor adherence were not confounding issues. In
2006, GINA (Global INitiative for Asthma) proposed the first separation in the definition of severity
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and control and, in 2007, a consensus report included for the first time the element of “time” and of
“specialist follow-up and treatment” [3]. This report stated that severe asthma applies to patients who
have refractory asthma who remain difficult to control despite an extensive re-evaluation of diagnosis
and management, and following an observational period of at least six months by an asthma specialist.
The first ERS-ATS guidelines on severe asthma in adults and children were published in 2014 [4].
Severe asthma was defined as “asthma that requires treatment with high dose inhaled corticosteroids
plus a second controller and/or systemic corticosteroids to prevent it from becoming “uncontrolled” or
that remains “uncontrolled” despite this therapy”. Emphasis was placed on the necessity to confirm the
diagnosis of asthma and exclude other conditions that may mimic asthma. In addition, the document
recognized that severe asthma is a heterogeneous condition consisting of different phenotypes. Once
the disease is properly characterized, the therapeutic targets can be identified, and proper treatment
can be adopted (Table 2).
Table 1. Lists of topics identified from the Delphi consensus.
Unanswered Questions Specific Topics
What are the different faces of severe asthma? The patient’s perspective
The clinician’s perspective
The researcher perspective
The scientific society’s perspective
The academic’s perspective
What makes asthma a severe disease? Comorbidities
Tolerance and resistance to β2-agonists
Aging
What are the most appropriate tools to
assess/monitor severe asthma? Second level functional assessment
Imaging
Biomarkers
Expert systems and artificial intelligence
Has severe asthma masked facades? COPD and ACO
Eosinophilic disorders
What are the challenges in treating severe asthma? Current algorithm
Drugs for COPD
Vitamin D
Future directions
Biologic drugs
Non pharmacological treatments
Severe asthma in acute or difficult settings Acute settings
Difficult settings (pregnancy)
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Table 2. Evolution of the definition of severe asthma.
Year Definition Endorsement
1999 (Chung K.F., Eur. Respir. J.) [1] difficult/therapy resistant asthma ERS
2000 (ATS workshop, Am. J. Respir.
Crit. Care Med.) [2] refractory asthma ATS
2007 (Chanez P., J. Allergy. Clin.
Immunol.) [3] severe asthma GINA
2014 (Chung K.F., Eur. Respir. J.) [4] severe controlled and uncontrolledasthma ERS/ATS
2018 (GINA pocket guide) [5] difficult-to-treat asthmasevere asthma GINA
2. The Different Faces of Severe Asthma
2.1. The Patient’s Perspective
The European Federation of Allergy and Airways Diseases Patients Associations has identified
some of the challenges and needs for severe asthma patients to raise the awareness on the impact of
severe asthma in patients’ and caregivers’ lives. First, to better control asthma, it is key to have a timely
and accurate diagnosis. Many patients wait for years before knowing which subtype of asthma they
suffer from and finally get a tailored and more effective treatment. Indeed, whereas an initial diagnosis
of asthma is commonly posed in primary care settings, a formal diagnosis of severe asthma requires a
more complex assessment following referral to a respiratory specialist. Although many advances have
been made in diagnostic assessment, there is an urgent need to grant access to the best tools for all
patients. Similarly, general practitioners need to be able to understand the results of the diagnostic
tests and to refer to specialists when needed. Shortening the patient journey is key to improving the
health-related quality of life for patients with severe asthma. In this respect, patients who present
to their general practitioner with difficult-to-manage asthma should be adequately assessed using a
structured and standardized methodology in order to avoid inappropriate escalation of treatment, and
streamline clinical assessment and management, therefore optimizing patient referrals. Establishing
clear referral pathways for patients with severe asthma is the first mandatory step to help patients
receive early and appropriate treatment.
Besides diagnostics, treatments have also improved and new drugs, such as biologics, are changing
the life of patients with severe asthma. Of course, the choice of the biologic drugs should also take
into consideration the individual needs of the patient. Patients are not always aware of the long-term
adverse effect of oral corticosteroids (OCS), and biologic drugs primarily aim at reducing, or abolishing,
their chronic use. On this basis, there is a growing call for severe asthma care to be less reliant on
the long-term use of OCS to prevent asthma attacks. The involvement of patients in research is key
to improve clinical developments in respiratory disease, in phenotyping severe asthma and taking
full advantage of personalized and precision medicine. Finally, the support of family, friends and
especially other patients, can motivate patients in keeping adherence to the treatment. Parents or
carers of young people with asthma need to know how to cope with the disease and their education is
essential for a good care of the patient. In this scenario, communication is crucial. Patients should
receive relevant information from their health-care professionals in a simple and clear format to better
understand the treatment options and the consequences of different management approaches. The
importance of good communication between health professionals and patients is recognized by the
latter, and improving communication is strongly advocated for a satisfactory outcome. Patients ask for
better skills to cope with their disease, and knowledge to properly recognize signs of asthma attacks or
avoid unnecessary or ineffective practices. Constant education on correct inhaler technique is also
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important to ensure the optimal effect of currently prescribed medications. There should be shared
decision-making between patients and their clinicians to ensure that optimal care is delivered.
2.2. The Clinician’s Perspective
When approaching a patient suffering from the most severe forms of asthma, who has reasonably
already seen several consultants, the clinician is forced to ask himself/herself the following questions:
is it really asthma? Can I “cure” him/her? What does he/she expect from me? How do I manage
exacerbations? How can I avoid further exacerbations? From a practical point of view, these questions
translate into the following themes: diagnosis/differential diagnosis; personalized/precision medicine;
prognosis; treatment of emergencies; barriers to health-care resources. The first question leads to a
“dynamic” process, meaning that it needs to be relaunched especially when patients do not respond
to current treatment. The diagnostic algorithm when approaching someone suffering from severe
asthma resembles that of asthma in its milder forms, and incorporates differential diagnoses; indeed,
confirmation of asthma requires that conditions that can mimic severe asthma (both pulmonary
and non-pulmonary) are ruled out. Indeed, symptom misattribution can generate confusion in the
diagnostic process. In this respect, objective measurements of variability in airway obstruction could
contribute to elucidate the clinical picture, and should always be pursued. However, bronchial
obstruction reversibility may be hard to achieve in severe asthmatics with long-standing disease, due
to the remodeling changes of the airway wall, therefore moving to an area of diagnostic uncertainty.
This process also includes the identification and treatment (or removal) of contributory factors,
such as non-adherence, poor inhalation technique, triggers and comorbidities. Methods to assess
non-adherence are mandatory in this population, and effective educational interventions aiming at
avoiding intentional and non-intentional non-adherence should be encouraged in daily practice. These
steps allow to move from a condition of difficult-to-treat asthma to that of severe asthma, which leads
to the correct therapeutic approach.
The second question raises from the shift paradigm in treating severe asthma, that is, anticipating
the biologics prior to the administration of long-term use of systemic corticosteroids, and poses a
challenge in terms of selection of the right treatment. The skills acquired through experience about the
criteria needed to choose among the biologic drugs are essential and require continuous educational
training and gaining of expertise. Eventually, what will guide therapy in severe asthma is not only
efficacy, safety and cost, but the ability to modify the natural course of the disease, which answers the
third question (prognosis). In this scenario, the respiratory community should strongly encourage
head to head clinical trials and those specifically looking at the search for disease modifiers. The fourth
question is extremely important: perhaps, learning about the exacerbation-prone phenotype in asthma
could help to prevent severe exacerbations. In this regard, written action plans could help to recognize
early signs of exacerbations, or worsening of symptoms, providing instructions for the management
of acute conditions. Finally (fifth question), the clinician pretends to have the tools and facilities to
properly treat his/her patients. In this regard, dedicated severe asthma service, or referral centers,
have been demonstrated to improve asthma control and quality of life, and reduce exacerbations and
emergency room visits, health-care use and oral steroid burden [6]. In this context, guidelines [5]
advise that asthmatic patients be managed by an experienced specialist multidisciplinary team (MDT).
An MDT case management approach has been shown to significantly reduce hospitalization in difficult
asthma patients with prior frequent admissions [7]. The MDT can allow the identification of modifiable
factors contributing to poor control, and proper management of overlapping conditions. Ideally, the
severe asthma MDT should include asthma educators and specialists [8] such as otorhinolaryngologists,
respiratory/allergy consultants and occasionally endocrinologists, rheumatologists, gynecologists,
radiologists and immunologists. Other collaborators such as nutritionists, physiotherapists and
psychologists may contribute to improve the outcomes by facilitating the communication with patients
and application of treatment strategies (Figure 1). A coordinated multidisciplinary action can be
particularly effective if expert primary care physicians are actively involved, both in the discussion of
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the actions to be taken, and in the opportunities for high-quality advanced training. Nowadays, severe
asthma is no longer an orphan disease.J. Clin. Med. 2019, 8, x FOR PEER REVIEW 6 of 27 
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2.3. The Funding Agency’s and the Researcher’s Perspective
From the perspective of a funding agency, the definition of severe asthma needs to be broad enough
in order to avoid restricting research proposals and stifling the diversity of research approaches in the
field. Research on severe asthma should involve patients who require high-dose ICS for asthma control,
those who cannot be controlled even with high-dose treatment and those who experience frequent
exacerbations. Th latter g oup is particula ly im ort nt when childhood asthma is c nsidered [9].
Funding agencies such as the Nat onal Institut of Allergy and Infectious Diseases (NIAID), which is
part of the US National Insti utes of Health (NIH), support research projects that target various aspects
of sev re sthm , with focus on prevention and management. I the context of these targ ts, it is
imperative that further understanding of the pathophysiol gy of severe asthma is attained. For NIAID,
the focus for pathophysiology research is on the role of the immune system, infectious processes and
airway homeostasis. Some principles that research on severe asthma needs to follow include careful and
in-depth immunophenotyping in association with functional airway/lung phenotyping, consideration
of both inherent and environmental inducers and their interaction, utilization of longitudinal, as
opposed to cross-sectional, cohort studies and a combination of both agnostic, hypothesis-generating
research and hypothesis-driven research within the same project. Longitudinal studies allow us to
observe disease oscillations within each patient and obtain a clearer picture of factors and pathways
that contribute to disease worsening (e.g., exacerbations) or disease stability. With the advent of
-omics methodologies, where the entire universe of a research field can potentially be captured,
hypothesis-generating research has stopped being a “fishing expedition” and has become essential in
reducing bias and promoting discovery. In handling -omics data, it is important to combine multiple
outcomes through a systems biology approach and to involve bioinformatics in designing studies and
conducting innovative data analyses [10]. In severe asthma research, animal models can be used to
test specific hypotheses related to the biologic role of a single mol cule or a gene/molecular network
identifi d throug human research. However, we should be cautious of th reverse approach, i.e.,
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animal models claiming to reflect severe asthma being used as the primary source of data for unveiling
the pathophysiology of the disease.
Prevention of severe asthma is a worthy goal. However, if a specific preventive intervention
for severe asthma were to be employed, we would need sensitive and specific early stage detection
methodologies to identify individuals, most likely children, at risk. Such methodologies are not
currently available. Furthermore, because severe asthma is a relatively rare condition, a large screening
effort would be required to identify individuals at risk. On the other hand, because severe asthma is a
sub-phenotype of a larger, persistent asthma phenotype, it is possible that a preventive intervention
targeting a wider population may also impact the incidence of severe disease. For example, early
multiple allergen sensitization in conjunction with recurrent wheezing constitutes a high-risk phenotype
for the development of asthma [11]. A subgroup of this phenotype appears to develop early airway
obstruction and may very well represent a specific group at risk of severe asthma. A preventive
intervention could be applied to such an entire multi-allergic/early wheezing group, as even those
children who may not end up developing severe asthma would benefit by not developing any chronic
lower respiratory disease.
Exacerbation-prone asthma should be considered part of the severe asthma spectrum. This is
a phenotype particularly relevant to the pediatric population. The importance of preventing the
development of this phenotype is that asthma exacerbations impact quality of life and education, incur
costs, can lead to major acute respiratory ailments and may also result in reduced lung function over
time [12]. Although asthma exacerbations are in their majority associated with upper respiratory
viral infections, the pathophysiologic pathways through which a viral infection converts to an asthma
exacerbation have only recently begun to be elucidated [12]. Furthermore, non-viral exacerbations are
not infrequent and their cause remains unknown. In addressing these knowledge gaps, studies should
involve longitudinal cohorts of individuals with exacerbation-prone asthma where upper and lower
airway, as well as systemic outcomes, are captured at the beginning of any cold symptoms, a few days
later or at the beginning of worsening asthma symptoms, regardless if those are preceded by upper
respiratory symptoms [13]. In addition to careful documentation of clinical symptoms and airway (nasal,
lung) function, these outcomes should include unbiased approaches such as nasal transcriptomics
(possibly with single cell analysis), proteomics and upper airway virome and micro/mycobiome
analysis. Concomitant sputum analyses would be ideal, but possibly limited by lower airway clinical
status. Such studies would not be complete without the collection of environmental data to assess
the relationship of asthma exacerbations with changes in the exposome. These studies require major
resources, but, given their potential, funding agencies should be able to offer appropriate support.
2.4. The Scientific Societies’ Perspective
Big data are nowadays providing a new scenario in evaluating several aspects of medicine.
Relevant insights are coming from registries whose structures are collecting standardized data. As
far as severe asthma is concerned, structured registries are currently available at regional, national
and international levels, thus allowing an analysis at country level but also the possibility to compare
demographic data between different nations’ registries. The Severe Asthma Network Italy (SANI)
registry is promoted by allergy (SIAAIC) and respiratory (SIP/IRS) Italian scientific societies, GINA Italy
and Federation of Italian Patient Associations (FEDERASMA), and has recruited severe asthmatics from
more than 50 asthma centers [14]. The first descriptive analysis was published on 400 subjects [15]. In
investigating the comorbidities, a high incidence of chronic rhinosinusitis with nasal polyps (CRSwNP)
was found. This is important given the impact on quality of life (QoL), the response to biologics and
the use of oral corticosteroids. The impact of CRSwNP is therefore prompting to investigate more
properly this comorbidity in any severe asthma patient. Integrated data can provide important insights
as in the Severe Heterogenous Asthma Registry Patient-centered (SHARP) and International Severe
Asthma Registry (ISAR) registries, thus strongly supporting the creation of national registries. Such
integration will provide a large body of new data. From registries on severe asthma, oral corticosteroid
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use has been declared in two-thirds of patients. This finding is consistent with other published reports,
thus strongly highlighting the overuse of oral corticosteroids (OCS) in severe asthmatics. On the basis
of this observation, SANI conducted a pharmacoeconomic analysis of the costs of OCS-induced side
effects, and the findings stressed the high cost per year of this pharmacological intervention [16]. This
is an example of how registries-derived information contributes to design strategies to reduce the high
impact of corticosteroids in severe asthmatics [17].
2.5. The Perspective of the Medical Educator
Asthmatics looking for medical care invariably interact with more than one health professional.
These figures and their collaboration increase with the complexity of the patient’s needs, which is high
in the most severe forms of the disease. Commonly, physicians’ attitudes when coping with chronic
diseases are rooted in the professionals’ experiences based on everyday general practice. There is
therefore a demand of continuing medical education to improve the quality of the medical care and to
ensure the best medical assistance. This educational process is founded on the delivery of high-quality,
unbiased and standardized training in order to facilitate greater participation of health professionals in
asthma management. National training centers at the primary or secondary level care should aim at
providing the skills to efficiently deal with the requests of the severe asthmatic patients. Standards
for asthma educators should be set in each country and supported by the scientific societies and the
academic institution with structured preparation and carefully constructed and validated certification
examinations. Unfortunately, a mismatch exists between the needs of the asthmatic patients and their
families and the delivery of high-quality education to health professionals. Interesting observations
related to the specific training proposed for current medical students come from the Italian experience.
Despite epidemiological data showing an increase of morbidity, disability and mortality of respiratory
disease all over the world, in Italy, postgraduate schools in respiratory diseases are found in only 25
out of 43 universities offering medical education, and the session on respiratory diseases during the
academic program is not always held by a professor of respiratory medicine. In the residents’ program
of Italian schools in respiratory medicine, almost 70% is reserved to the development of training
activities [18]. When looking at the topic of asthma, clinical immunology and complete pulmonary
functional tests are mandatory requirements for any specialization program in respiratory medicine. In
this respect, the GINA documents [5,19] are excellent tools that should be integrated in the curriculum,
given the rapidly evolving concepts in this field. It is obvious that the training course for schools of
respiratory diseases should include the most updated knowledge in the underlying physiological
mechanisms and comorbidities, for the overall management of the asthmatic disease, especially in
its severe forms. It is logical to predict that guidelines are more likely to change practice when they
are disseminated to clinicians using a specific educational intervention or are included in courses for
university graduates.
3. What Makes Asthma a Severe Disease?
Severe asthma differs from the mildest (or less severe) forms of the disease in several respects.
Certainly, severe asthma is characterized by a component of irreversible airflow obstruction and
peripheral airways disease, with features of mainly neutrophilic inflammation, although in some
subgroups it is associated with persistent eosinophilic inflammation, in a mixed type inflammatory
phenotype. This suggests that severe asthma might be a different form of the disease, rather than mild
asthma gone bad. Structural changes associated with persistent airflow limitation in asthma, also
referred to as airway remodeling, include thickening of the airway wall due to subepithelial fibrosis,
hypertrophy or stiffening of airway smooth muscle and hyperplasia of mucous glands and goblet cells.
In addition, edema, vascular dilatation and increased numbers of blood vessels may contribute to
the thickening of the airway wall. Inflammation per se has been suggested to be responsible for part
of the remodeling process. Neutrophilic inflammation in general appears to be associated with the
severity of asthma, although a subpopulation of severely asthmatic patients exhibits elevated numbers
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of eosinophils. In addition to non-reversible features of airway obstruction, the severe asthmatic
phenotype is characterized by a condition of air trapping, as a result of early airway closure during
expiration, which is likely to facilitate excessive airway narrowing, being therefore responsible for
severe, and even fatal, asthma attacks. These pathological and functional alterations set the basis for
the occurrence of several clinical patterns of severity, whose heterogeneity is influenced by endogenous
or exogenous factors. The following sections highlight the key role of comorbidities, beta-2 agonist
resistance and aging in complicating the course and the management of the disease.
3.1. Comorbidities
Comorbidities associated with severe asthma are common, complicate the overall management and
influence patient outcomes. They can often interact, contributing to poor disease control and sometimes
mimicking asthma symptoms. Several comorbidities are more common in severe asthma than in mild to
moderate asthma or in healthy individuals. While some comorbidities, such as gastroesophageal reflux
(GERD), bronchiectasis and COPD, are well recognized [20], many others remain unrecognized and
detected only in an expert specialist setting. There are data indicating that the presence of comorbidity
is associated with worse outcomes in patients with asthma. As an example, the presence of chronic
rhinosinusitis is a strong risk factor for frequent exacerbations [21]. Comorbidities can be grouped into
two large domains, the respiratory and the extra-respiratory ones [22]. Respiratory comorbidities can
generally be classified according to their anatomical site along the respiratory tract: upper, middle
and lower respiratory tract disorders. Most of them are usually known and therefore assessed during
evaluation of the patient with severe asthma, while others such as dysfunctional breathing or vocal
cord dysfunction [21,23], if not properly recognized, may lead to inappropriate escalation in asthma
treatment. Extra-respiratory comorbidities are even more complex in the management of patients with
severe asthma. It is therefore necessary to standardize a multidimensional approach in managing
the patient with severe asthma, using screening questionnaires. The use of validated screening
questionnaires for each comorbidity can increase their detection compared with a clinical consultation
alone, guide the clinician to confirm the presence of the comorbidity and then address this problem with
a multidisciplinary team. A recent meta-analysis has collected studies that systematically addressed
comorbidities as part of their protocol, demonstrating that this approach leads to improvements in
asthma control, quality of life and exacerbation rate [22].
3.2. Tolerance and Resistance to β2-Agonists
Inhaled β2-agonists are indicated in the treatment of asthma. In the last century however,
paradoxical asthma exacerbations and deaths have been associated with long-acting β2-agonists
(LABAs), mostly when used without ICS. Preclinical and clinical studies documented that long-term
use of LABAs was associated with increased effects of airway hyperresponsiveness (AHR) and loss
of bronchoprotection [24]. In recent years, our knowledge on molecular pathways related to G
protein-coupled receptors (GPRs) activation allowed us to understand the mechanism involved in
desensitization and tolerance toβ2-adrenergic receptors (β2-AR) [25]. The canonic mechanism of action
of these drugs is the activation of β2-AR on airway smooth muscle leading to G protein activation and
subsequent generation of c-AM: cAMP subsequently phosphorylates protein kinase A (PKA), involved
in the control of airway smooth muscle tone, leading to reductions in intracellular calcium, smooth
muscle relaxation and bronchodilation. However, there is now growing evidence that suggests that the
binding of β2-agonists to β2-AR is pleiotropically coupled to many intracellular pathways, whereby,
depending on the state of the β2-AR when activated, a subset of different intracellular responses can
be triggered. Studies over the past 15 years have unveiled novel signaling pathways for β2-AR. Apart
from the canonical mechanism of which activation involves the increase in cAMP signaling, another
signaling pathway has been identified that involves activation of downstream mitogen-activated
protein kinases (MAPK) like ERK1/2, JNK and/or p38 by arrestin. This is called biased agonism (or
functional selectivity), and this type of activity has now been observed with different types of GPCRs,
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not just β2-AR. These different responses, that depend on what state the receptor is in when the ligand
binds to it, can subsequently influence the intracellular signaling that in turn can influence the efficacy
of β2-AR ligands. These findings explain why the long-term treatment with β2-agonists could be
related to a loss of efficacy and tolerance induced by desensitization following repeated activation [26].
3.3. Aging
It is clearly established that asthma in the elderly exists and is different from COPD under
clinical and pathology aspects. However, it is less clear whether asthma in the elderly is more severe
compared with younger individuals. Unfortunately, studies directly exploring severe asthma in the
elderly are scanty. To overcome this, it could be of interest to explore whether aging is a risk factor
for uncontrolled asthma. Studies on asthma control [27] demonstrated poorer control in the elderly
compared with younger patients. However, the elderly may not perceive their symptoms, due to
a blunted perception of dyspnea [28], and dyspnea may be misinterpreted or not reported, often
considered as due to aging. In elderly patients, the presence of comorbidities and the low adherence to
inhaled medication can negatively influence asthma control [29]. Indeed, the prevalence of chronic
concomitant diseases is higher in the elderly and unintentional non-adherence is often present in this
population. Cognitive impairment and lack of proper inhaled technique of respiratory drugs could
often account for unintentional non-adherence in the elderly. A cluster analysis [30] on elderly asthmatic
phenotypes demonstrated that patients with a long symptom duration and marked airway obstruction
have a shorter amount of time to first acute asthma exacerbation. In the elderly, exacerbations are
often serious: the age-adjusted mortality rate is higher in asthmatics aged 65 years and more. This
observation could be due to the well-known issue of under-diagnosis and under-treatment of asthma in
the elderly [31]. Furthermore, the blunted perception of dyspnea in the elderly could lead the patients
to a severe airway obstruction without “alert signals” and therefore without the appropriate use of
(rescue) medications. Finally, the elderly asthmatics are at risk of severe airflow limitation. It has been
proposed that the combination of physiological age-related changes in the lung (the so-called senile
lung) with the typical features of asthma in the elderly (e.g., slight differences in the inflammation
patterns, medication adherence) may lead to more severe airway obstruction and, in turn, to more
difficult-to-manage asthma in the elderly [32]. Asthmatics seem to lose some protective mechanisms
with aging, such as the bronchodilator effect of deep inspiration [33], and they also show more severe
airway obstruction compared with younger asthmatics [27]. In conclusion, several evidences show
that older age could be a risk factor for difficult-to-control or even severe asthma.
4. What Are the Most Appropriate Tools to Assess/Monitor Severe Asthma?
4.1. Second Level Functional Assessment
Commonly employed spirometric tests, such as forced expiratory volume in one second (FEV1),
forced vital capacity (FVC) and the ratio of FEV1 to forced vital capacity (FEV1/FVC), represent
first-level functional assessments and are currently used in clinical practice to establish the degree
of functional impairment and the magnitude of reversibility of bronchial obstruction. Measures of
lung volumes, such as residual volume (RV) as well as total lung capacity (TLC), are, to some extent,
correlated to the functional state of the peripheral airways. The importance of the peripheral airways
in the pathological processes leading to severe asthma and the correlations with the severity of clinical
manifestations and with patient-reported outcomes has led to the concept of severe asthma as a disease
mainly of the small airways [34].
The single-breath nitrogen (sbN2) wash-out test is another non-invasive tool to detect early closure
of peripheral airways. It is based on the detection of regional differences in ventilation distribution,
represented by the phase III slope of the flow-volume curve following the wash-out test. Asthma
patients who have frequent exacerbations (≥2 per year) have a higher degree of small airway disease
measured with the single-breath nitrogen wash-out test than patients with infrequent exacerbations (<2
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per year), whereas their FEV1 and FEV1/FVC are similar [35]. The multiple breath nitrogen wash-out
(MBW) test measures functional residual capacity (FRC). The esophageal balloon technique represents
the gold standard for the measurement of changes in pleural pressure, and is one of the most reliable
methods to disclose the premature closure of small airways. Although a comprehensive lung functional
assessment is advocated based on their clinical consequences in terms of identifiable therapeutic targets,
this can be reasonably conducted only in a limited number of referral centers.
4.2. Imaging
Lung and airway imaging have the potential to improve our ability to quantify treatment success.
There are several imaging modalities available for the lungs: chest radiograph (CXR), multi-detector
computed tomography (MDCT), magnetic resonance (MR), positron emission tomography (PET),
fluoroscopy, ultrasound (US) and optical coherence tomography (OCT). One important use of imaging
modalities such as CXR and MDCT is to identify co-morbidities not related to asthma but which
can nevertheless mimic or worsen asthma symptoms. These include pneumonia, pneumothorax,
pneumomediastinum, allergic bronchopulmonary aspergillosis, chronic eosinophilic bronchitis and
eosinophilic pneumonia and eosinophilic granulomatosis with polyangiitis for which specific treatment
should be offered [36]. While modalities such as MDCT and MR have been used on a research basis to
image changes in the lungs and airways specific to severe asthma, their usefulness to direct treatment
is unclear. MR imaging using hyperpolarized noble gases such as 3He and 129Xe can be used to image
ventilation inhomogeneity [37]. One can see areas of low and no ventilation in individuals with asthma
at baseline and during acute exacerbations. However, it remains unclear how this information will
improve our ability to treat severe asthma. CT scanning can be used to image air trapping and airway
wall thickness [38]. With worsening disease, air trapping increases. This can now be visualized easily
with 3-D reconstructed CT images. However, the same information can be acquired with less cost and
no radiation exposure using body-plethysmography. While MDCT can visualize airway walls in vivo,
MDCT is unable to identify any of the structures within the wall and can only visualize the wall as a
solid structure. It is well established that the airway walls of individuals with asthma, especially the
most severe kind, fatal asthma, are thicker on average than healthy individuals [39]. This has also been
demonstrated in vivo using MDCT [40]. However, the difference in wall thickness in vivo is small and
there is considerable overlap between healthy and diseased airways. Therefore, thicker airway walls
based on MDCT images are unlikely to be helpful in identifying and treating those with severe asthma.
OCT is a newer imaging technology that can visualize the microstructure of biological structures
in vivo. In addition, recent advances allow OCT to generate three-dimensional images with micrometer
resolution. OCT does not use ionizing radiation and can generate images in real-time. OCT is the
optical analog to B-mode ultrasound. However, instead of using sound waves, OCT uses low-coherence
near-infrared laser light. OCT can also be deployed through a standard fiberoptic bronchoscope, making
it easily deployable in clinical situations. The greatest strength of OCT is its ability to differentiate the
various tissue layers in the airway wall [41]. The most important tissues in asthma are the epithelial
layer, the basement membrane layer, the airway smooth muscle (ASM) layer and the glands. The use
of OCT with bronchial thermoplasty (BT) therapy for severe asthma has several benefits. First, OCT
may be useful in optimizing the location of maximum ASM for treatment. Second, OCT can verify the
treatment success of BT (i.e., changes in the structural components of the airway wall post-BT). Third,
OCT may be valuable in selecting the right patients for BT treatment. OCT and BT in combination may
be an optimal way to treat severe asthma.
4.3. Biomarkers
The so called “SAVED” model has been suggested to outline the utility of a proposed biomarker:
“Superior”— outperforms current practice; “Actionable”—having the potential to change patient
management; “Valuable”—able to improve patient outcomes; “Economical”—to be cost-saving or
cost-effective; “Deployable”—technologists should be in place for their assessment [42]. Figure 2
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describes the steps required to move from a research setting to clinical applicability. The quest for
biomarkers is linked up to the introduction into the treatment of asthma of formulations, many of
which are biologic products targeting specific molecules driving the different asthma endotypes.
Thus, (induced) sputum cytology provides evidence of eosinophilic, neutrophilic, mixed cellular, as
well as low cell numbers (paucigranulocytic) profiles of airway inflammation in asthma [43]. The
separate cellular profiles are orchestrated by a plethora of cytokines against the background of specific
neural networks. Our understanding is most advanced about eosinophilic, high T-helper (Th) type 2
airway inflammation. It is identified by high blood and sputum eosinophils, high serum total and
allergen-specific immunoglobulin (Ig) E, interleukin (IL) 5, 4 and 13 and other mediators upstream the
inflammatory cascade like IL33, IL25 and thymic stromal lymphopoietin (TSLP). Biologic therapies
and also smaller molecules have been tailored to block these molecules or their receptors. On the other
end of the spectrum are the cases of non-eosinophilic asthma. Its pathogenesis is poorly understood,
particularly for a neutrophil cellular profile of the airways, with corresponding cytokines from Th1 and
Th17 cells, and the involvement of type 3 innate lymphoid cells, leading to activation of macrophages
and release of neutrophil chemokines such as C-X-C motif chemokine ligand 8. In line with the SAVED
model, a lot of hope is placed on biomarkers of the exhaled human breath [44]. Thus, fractional
exhaled nitric oxide (FeNO) is already broadly assessed in clinical trials of formulations for patients
with eosinophilic, high Th2 airway inflammation. New approaches for capturing exhaled biomarkers
rely on analysis of breath condensate, but are mostly at an experimental stage. Alternatively, integral
methods for non-invasive assessment and monitoring of airway inflammation and remodeling exist:
exhaled breath temperature measurement and electronic sensing (e-sensing) technologies (electronic
nose), which are currently under development and/or validation.
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4.4. Expert Systems and Artificial Intelligence
Artificial intelligence (AI) is the simulation of human intelligence processes by computer systems.
The expert systems (ES) are one component of AI. They are consulted to obtain advice, suggestions and
recommendations on issues that fall within the human experts’ knowledge and are widely used in many
different fields of activities (among which medicine). Typically, an ES incorporates: a knowledge base
containing accumulated experience, and a rules engine (a set of rules for applying the knowledge base
to each particular situation that is described to the program); the system’s capabilities can be enhanced
with additions to the knowledge base or to the set of rules. In brief, an ES is a computer program that
uses AI technologies to simulate the judgment and behavior of a human that has expert knowledge
and experience in a particular field. Current systems may include machine-learning capabilities that
allow them to improve their performance based on experience, just as humans do. Recently, a panel of
Italian pulmonologists developed an ES for assisting the identification of individuals suffering from
chronic obstructive lung disease (COLD) in primary care settings [45]. By removing diagnoses that
cannot be made based on only the questionnaire, the overall accuracy of the COLD ES was 97.50%.
This seems promising for a future use of the ES in different settings, including primary care, and raises
the possibility that a similar effort can be made for the diagnosis of severe asthma.
5. The Masked Facades of Severe Asthma
5.1. COPD and ACO
It is easy to differentiate pure asthma from pure COPD because they reflect the extremes of a
spectrum, but it is widely recognized that there are patients, especially those who are elderly, who
present with features of both asthma and COPD, leading to an overlap [46]. The presentations
of these illnesses can converge and mimic each other, making it difficult to give these patients
a diagnosis of either condition also because some of the mechanisms driving airway obstruction
and hyperresponsiveness are similar in asthma and COPD, and some are different. In any case,
the association of asthma and COPD in the same patient has been designated mixed phenotype
asthma-COPD or asthma–COPD overlap (ACO). However, a precise definition of ACO is lacking and
this makes it difficult to categorize the contrasting distinctive features of this phenotype. Furthermore,
ACO presents as multiple phenotypes, some including more features of asthma than COPD and the
opposite in others [47], such as patients with COPD and eosinophilic inflammation, patients with
asthma and severe disease or who smoke, in whom there is predominantly neutrophilic inflammation,
and patients with asthma who have largely irreversible airway obstruction due to structural changes.
Consequently, it has been suggested that ACO includes two main conditions, smoking asthmatics and
eosinophilic COPD patients (≥300 blood eosinophils/µL), with different medication requirements and
prognosis that should not be pooled together. Use of ≥300 blood eosinophils/µL as a treatable trait
should be recommended [48]. The eosinophilic COPD should identify those COPD patients that would
benefit the most from ICS. However, studies have not shown differences in the response to ICS therapy
based on eosinophil counts, particularly in those with mild-to-moderate COPD [49,50]. Nonetheless,
because of risk in patients with asthma with LABA monotherapy, it has been suggested that ICS (usually
associated with a LABA) is the preferred therapy in ACO. The term ACO may be a relatively simple
way to avoid excessive diagnostic investigations and streamline therapy. However, due to the absence
of a clear definition and the inclusion of patients with different characteristics under this umbrella
term, it may not facilitate treatment decisions, especially in the absence of clinical trials addressing
this heterogenic population. Therefore, there is an open debate on whether the term “ACO” should
be abandoned because it does not identify a clearly independent disease entity. This heterogeneity
indicates a wide range of disease mechanisms [51]. Asthma and COPD are not only heterogeneous
diseases but also associated with complex medical conditions. Different molecular characteristics
associated with different endotypes may present in varying proportions in any given patient.
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5.2. Eosinophilic Disorders
Among clinical conditions related to a pathogenic role of eosinophils, hypereosinophilic syndromes
(HES), defined as conditions in which there is an elevation in the peripheral blood absolute eosinophil
count greater than 1500/mL on at least two separate detections, should be included. HES can be divided
in primary and secondary forms and, among them, eosinophilic granulomatosis with polyangiitis
(EGPA), which is closely associated with asthma [52]. According to the American College Rheumatology
classification, the diagnosis of EGPA can be made when at least four criteria are present [53]. As
mentioned, asthma is a peculiar manifestation of EGPA, often presenting several years before EGPA,
starting in association with CRSwNP. EGPA is classically considered a Th2-driven inflammatory
response. Peripheral T cell lines from patients with EGPA produce large amounts of IL-4, IL-5 and IL-13.
Elevated IL-5 is found in serum and bronchoalveolar lavage fluid of patients with active disease [54].
The potential role of Th17 and B cells, producing anti-neutrophil cytoplasmic antibodies (ANCA), in the
pathogenesis of EGPA has been suggested [55]. A higher rate of Th17 cells able to secret larger amounts
of IL-17A is found during active disease. Similarly, a reduced proportion of regulatory T cells, which
have a suppressive effect on Th17 cells, and aberrant regulatory T cell function have been implicated.
Despite a correct treatment with high doses of systemic corticosteroids, a significant proportion of
patient relapses and immunosuppression is needed. In addition, the majority of patients do not achieve
a good control of asthma symptoms despite inhaled and systemic corticosteroids. A clinical trial
performed in EGPA patients with mepolizumab (300mg/4weeks) showed that, in comparison with
the placebo, the biologic is able of inducing a remission of the disease in a significant proportion of
patients even if after interruption of treatment they relapse [56].
Although not a frequent comorbid condition, eosinophilic esophagitis (EoE) carries some very
interesting inflammatory and immune characteristics that are worth discussing as they include both
similarities and differences from asthma. EoE is a chronic atopic clinical-pathologic disease defined by
eosinophil infiltration limited to the esophageal epithelium [57,58]. Once considered a rare disease,
it has now reached a yearly incidence of 1–2/1000 in the US with a 50–70-fold increase in the last
decade [59]. It presents with symptoms of esophageal dysfunction such as dysphagia, food impaction,
esophageal strictures, reflux-like symptoms, vomiting but also post-prandial cough and chest pain that
can mimic asthma. Currently, diagnosis and follow-up of treatment of EoE are based on the count of
eosinophils per high power field (eos/hpf) in esophageal biopsy obtained via esophagogastroduodenal
endoscopy (OGD). EoE has many similarities with asthma in terms of inflammatory process and
pathogenesis; however, the recent clinical trial with biologics as treatment of EoE points out some
differences with asthma. EoE appears to be part of the atopic march and to have Th2-predominant
inflammation driven by chronic antigen exposure. However, food but not environmental allergens
seem to be significant triggers of EoE [60]. The complex nature of the immunological response
constitutes a major obstacle in the development of targeted treatments. Eosinophils are very useful for
diagnosis and monitoring of the disease but are not essential in EoE development. Indeed, anti-Il-5
monoclonal antibodies (i.e., reslizumab or mepolizumab), which are effective in blocking IL-5, have
been ineffective in treating symptoms and inflammation in EoE in both children and adults [61,62].
Even if EoE patients are atopic and often produce IgE against environmental and food allergens, IgE
does not appear essential to trigger or maintain EoE inflammation. Indeed, classical food allergen
testing such as measurement of specific food IgE by in vivo (i.e., skin prick test) or in vitro testing
(i.e., ImmunoCap, ISAC), has been unable to predict EoE food allergen triggers. In an animal model,
EoE could still develop in the absence of IgE, and children who outgrow IgE-mediated food allergies
are at risk of developing EoE. Therefore, it is not a surprise that omalizumab has been ineffective in
treating symptoms and inflammation in EoE [63]. Anti-IL-4/IL-13 antibodies such as dupilumab with
broader efficacy against Th2 inflammation have been shown to be effective in reducing inflammation
and dysphagia in a small double-blind study placebo-controlled study [64]. Anti-IL-13 antibodies
have shown efficacy against inflammation but not dysphagia [65]. In conclusion, EoE is an emerging
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comorbidity of asthma, and its presence may lead to use personalized medicine and therapies that can
treat EoE and asthma at the same time.
6. Challenges in the Treatment of Severe Asthma
6.1. Current Algorithm (as Proposed by GINA)
The Global Initiative for Asthma, launched 25 years ago, produces a yearly updated clinically
oriented, evidence-based strategy to help the translation of evidence into clinical practice, to promote
optimal care of this disease around the world [6]. Among the various documents produced by GINA,
summaries of its recommendations, related to current knowledge obtained from published research
and guidelines, we find “Pocket Guides”, including a recent one on Diagnosis and Management of
Difficult-to-treat and Severe Asthma in Adolescent and Adult Patients, first published in November
2018 and updated in April 2019 [19]. This booklet is intended for use by general practitioners, lung
specialists and other health professionals involved in the management of patients with asthma. The
recommendations in this Pocket Guide are based on evidence from good-quality systematic reviews
or randomized controlled trials or, lacking these, good observational data, and on consensus by
expert clinicians and researchers, when evidence is not available. The booklet includes a decision
tree produced with the collaboration of experts in human-centered design, to enhance the usefulness
of this document for end-users. The Pocket Guide should be ideally used in conjunction with the
full GINA 2019 report. The prevalence of severe asthma will vary by country according to access to
medications and the health system. In one study, 17% of asthma patients were considered to have
“difficult-to-treat asthma” characterized by poor symptom control and/or exacerbations despite GINA
Step 4 or 5 treatment. This was usually due to sub-optimal management and/or patient behavior, with
only about 4% of patients with asthma having “truly” severe asthma, having still poor symptom control
despite optimal management, good inhaler technique and good adherence to therapy [66]. The Pocket
Guide also emphasizes that severe asthma is heterogeneous, with different characteristics (phenotypes)
and different mechanisms of development or persistence (endotypes). Recommendations are therefore
made for asthma related to patients with features of either Type 2 or non-Type 2 inflammation. The
decision tree changed previous flowcharts and text-based information to a more detailed visual format.
Specific identification of items related to diagnosis, decision points and treatment, in addition to locus
of care considered and reminders about ongoing issues are clearly indicated. The first four sections of
the decision tree are for use in primary care and/or specialist, the next three sections are mainly relevant
to respiratory specialists and the last one is about collaborative care between the patient, the general
practitioner, specialist and other health professionals. The document stresses the need to proceed with
a systematic investigation of difficult-to-treat asthma, to distinguish asthma management problems
from truly severe asthma and also provides relevant information on new biologics.
6.2. Drugs for COPD (Do They Also Work in Severe Asthma?)
The pharmacological classes used in asthma and in COPD are pretty similar. The differences are
mainly in the strategy of the use of the medications. Traditionally, in obstructive lung diseases, inhaled
and oral treatments have been firstly tested in asthma and then evaluated for COPD. The exception
being triple therapy with ICS/LABA/long-acting muscarinic antagonists (LAMA) that has been widely
used for a long time (as open triple with more than one device) in COPD before being tested in
severe asthma [67]. Even the use of triple therapy in one single device has been developed in COPD
before being tested in severe asthma. At the moment, we still do not have the full results of the trials
comparing triple therapy in severe asthma. What we know from the PrimoTina study [67] is that the
addition of tiotropium to the high dose ICS/LABA combination budesonide/formoteterol improves lung
function and reduces exacerbations in a selected population with fixed airflow limitation, i.e., a very
specific subgroup of severe asthma, those more similar to COPD. Conversely, triple therapy in COPD is
effective in reducing exacerbation risk compared with ICS/LABA and LABA/LAMA combinations: in
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the latter case, the higher the blood eosinophils counts, the greater the magnitude of the superiority [68].
Whether it is the same in severe asthma has still to be evaluated. The level of eosinophils is (one of)
the more popular biomarker used in severe asthma to assess the eligibility for biologic treatments.
The same approach has been tested in COPD, following the same concept on the characterization of
subjects: high blood eosinophils plus frequent exacerbations. With mepolizumab, the magnitude of the
effect was lower than expected but the study clearly showed that the efficacy of mepolizumab is clearly
selective on the prevention of exacerbations requiring systemic corticosteroids, but was ineffective in
reducing exacerbations requiring antibiotic treatment. Though not surprising, this evidence identifies
the population (phenotype) where the efficacy of an anti-IL5 should be expected: those patients
with exacerbations not requiring antibiotics that more likely have eosinophilic exacerbations [69].
The results with anti-IL5Ra in COPD are overall less convincing [70]. However, subgroup analyses
are being conducted to identify the population that could benefit from anti-IL5Ra treatment. In
severe asthma and in severe COPD, clinical trials have tested the efficacy of macrolides (in particular
azithromycin, with different strategies/dosages) as an option for patients not responding to other
treatments, particularly for the prevention of exacerbations. In both clinical conditions, the efficacy of
this approach has been documented, at the risk of development of antibiotics resistance. Given the
WHO warning on appropriate use of antibiotics as resistance is becoming a global threatening problem,
the chronic use of azithromycin should be limited to a highly selected population and should be the
last resort in severe asthma or COPD patients where any other treatment has failed. A number of new
molecules are under investigation both in severe asthma and COPD. Likely, we will see a cross-over of
the evaluations moving from asthma to COPD or, occasionally, vice versa. Nothing new under the sky.
6.3. Vitamin D
A significant body of epidemiological evidence suggests associations between vitamin D
insufficiency and worse asthma control. However, clinical trials of vitamin D supplementation
in asthma, with varied design and dosing regimens, have produced variable outcomes. Most recently,
meta-analyses and systematic reviews indicate that vitamin D reduced asthma exacerbations, had
steroid-sparing effects and protected against acute respiratory tract infection. These effects were
greatest in subjects who were very vitamin D-deficient and most effective when given frequently, i.e.,
daily/weekly, but not as a bolus [71,72]. Vitamin D beneficially modulates diverse immunological
pathways linked to heterogeneous asthma endotypes. Allergic asthma is frequently characterized
by the failure of tolerance and the development of pathologic responses to inhaled aeroallergens.
Vitamin D may improve control of allergic asthma through demonstrated actions on dendritic cells
to promote a tolerogenic phenotype, to enhance the frequency of inhibitory molecule expression
(e.g., IL-10, CTLA4, Foxp3) by T regulatory cells (Treg), to reduce class switching to IgE and increase
IL-10 synthesis in B lymphocytes and to decrease mast cell activation. In non-allergic eosinophilic
asthmatic inflammation, vitamin D may act on bronchial epithelial cells to enhance antimicrobial and
anti-inflammatory functions, block the activity of the alarmin IL-33 through stimulation of a soluble
receptor antagonist, sST2, as well as dampen ILC2 and eosinophil activation. In glucocorticoid or
treatment refractory asthma, vitamin D may act on bronchial epithelial cells to promote antimicrobial
and anti-oxidant actions, to suppress Th17-associated cytokines, enhance anti-inflammatory IL-10
synthesis and on neutrophils to promote antimicrobial activity and reduce pro-inflammatory cytokine
production. Vitamin D is a potent inducer of antimicrobial mechanisms in many cell types, which is of
relevance in the control of infection-precipitated asthma exacerbations [73]. These mechanisms support
a role for vitamin D in secondary prevention to reduce exacerbations and inflammation in asthma.
These data indicate the potential that restoring vitamin D sufficiency can incrementally improve asthma
control in existing disease. The most recently emerging studies suggested a role for vitamin D in the
primary prevention of asthma. Vitamin D deficiency is often profound in pregnancy [74]. Offspring
of women with high vitamin D levels in the first trimester that were sustained by supplementation
during pregnancy had a significant reduction in recurrent wheeze and asthma at age 3 years [74,75].
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6.4. Current Treatment
In an apparently uncontrolled asthmatic patient under standard inhaled therapy, the GINA
document [6] suggests the following actions: a) check for adherence and evaluate the inhaler technique
(in several cases, adherence to regular treatment is poor, inhaler technique is incorrect and when
these aspects are appropriately corrected, asthma may result under control); new “intelligent” devices
checking inhaler technique and facilitating drug inhalation may improve adherence; b) assess and
appropriately treat asthma-associated comorbidities as these may be responsible for lack of control
and their appropriate management may result in a better management of the disease; c) optimize
current pharmacologic treatment using high-dose (and sometimes supramaximal doses) of ICS
associated with LABA and frequently with tiotropium or montelukast. New high-strength ICS/LABA
combinations, like BDP200/formoterol or fluticasone furoate/vilanterol 184/22, have demonstrated
greater efficacy in improving symptoms and lung function in comparison with lower doses of the
same combinations [76,77]. Furthermore, the SMART strategy in patients already treated with a
regular high-dose budesonide/formoterol combination was able to reduce the exacerbation rate better
than other options [78]. In severe uncontrolled asthmatics, the addition of tiotropium to high-dose
ICS/LABA resulted in a significant improvement in FEV1 and a mild but significant reduction in
severe exacerbations [67]. Finally, in a real-life open study, the addition of montelukast to ICS/LABA
combinations improved asthma control over time [79]. Despite any optimization of the current
therapy, a large portion of severe asthmatics remains uncontrolled. In these patients, GINA guidelines
recommend to proceed to pheno-endotyping for the identification of type 2 asthma, for which old
(anti-IgE) and new (anti-IL5 or anti-IL5R, or anti-IL4/13R) biologics are effective, as demonstrated in
phase III trials where these drugs reduce by about 50% the rate of severe exacerbations in comparison
with placebos, and in oral steroid-sparing studies. Clinical indications are similar for all these biologics
(severe uncontrolled asthma despite high level of current therapy), but the prescriptive criteria are
different. Anti-IgE treatment (omalizumab) has been shown to be effective in early onset severe allergic
asthma, often associated with allergic rhinitis or chronic urticaria, with definite levels of serum IgE
plus allergic sensitivity to perennial allergens. A large amount of real-life observational studies have
demonstrated that omalizumab is effective independently from the level of blood eosinophilia [80],
although its efficacy seems lower in older patients and in patients with persistent eosinophilia [81].
Efficacy of anti-IL5 or anti-IL5R (mepolizumab or benralizumab) has also been shown in late-onset
severe asthma [82], often non-allergic and with nasal polyps, with blood eosinophilia (cut-off values
are slightly different for mepolizumab and benralizumab). Blood eosinophil levels, the rate of
severe exacerbations and the presence of nasal polyps are good predictors of response to anti-IL5 or
anti-IL5R [83]. Treatment with anti-IL4/13R (dupilumab) has been demonstrated to be effective in
late-onset asthma, often allergic and with nasal polyps or atopic dermatitis (on which dupilumab is
strongly effective) [84], associated with mild blood eosinophilia (>150 cell/µL) and/or increased levels
of exhaled nitric oxide (>25 ppb). Therefore, considering the similar clinical and biological profile
for the prescription of these biologics, the presence of comorbidities on which the same biologics
are effective may guide the choice of the preferred treatment. Unfortunately, up to 50% of severe
uncontrolled asthmatics are not affected by type 2 asthma: in these patients, new targets for effective
treatment are needed.
6.5. Future Directions
It is increasingly recognized that severe asthma comprises several distinct phenotypes or endotypes
that may require specific therapies and that precision medicine will be increasingly used more
effectively in managing these patients. Figure 3 describes the main therapeutic targets in severe
asthma. Approximately 50% of patients with severe asthma have a type-2 immunity (T2) pattern
of inflammation, with increased eosinophils, and these patients usually respond well to antibodies
against IL-5 (if blood eosinophils are high and there are frequent exacerbations) or anti-IL-4Rα (if
exhaled nitric oxide (FeNO) is high and especially if they suffer from concomitant atopic dermatitis and
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rhinosinusitis) [85]. Tezepelumab, which targets TSLP, may be even more effective as it is upstream of
both IL-4/13 and IL-5, but may also target non-T2 mechanisms [86]. Anti-IL-33 (such as etokimab) and
anti-IL-33 receptor (ST2) may also have a similar broader efficacy. A much greater challenge is the
development of more precise therapies for non-T2 severe asthma, which includes neutrophilic asthma
and paucigranulocytic asthma. So far, targeting neutrophilic asthma has included unsuccessful efforts
with CXCR2 antagonists, which inhibit the recruitment of neutrophils into the airways by blocking the
effects of CXCL8 and related chemokines [87,88]. Similarly, blocking IL-17 receptors with brodalumab
was also ineffective, although patients with severe neutrophilic asthma were not selected [89]. There
is evidence that NLRP3 inflammasome activation may be important in neutrophilic severe asthma,
including asthma associated with obesity, and associated with increased IL-1 and caspase-1 [90].
An inhibitor of NLRP3 is effective in a mouse model of severe neutrophilic asthma [91]. A novel
endotype of severe asthma has been recognized from the U-BIOPRED cohort of severe asthma that
involves IL-6 receptor trans-signaling that may respond specifically to an IL-6 receptor antibody, such
as tocilizumab [92]. Novel broad-spectrum anti-inflammatory treatments, such as phosphodiesterase-4,
JAK and IRAK-4 inhibitors may be useful in non-T2 inflammation [93,94]. Macrolide antibiotics
are also effective in reducing exacerbations of non-T2 asthma [95,96]. The potential for antibiotic
resistance is leading to a search for non-antibiotic macrolides that retain anti-inflammatory effects. For
paucigranulocytic patients, anti-inflammatory treatments are not indicated, but they may benefit from
adding long-acting muscarinic antagonists [67]; highly selected patients may benefit from bronchial
thermoplasty and targeted lung denervation.
J. Clin. Med. 2019, 8, x FOR PEER REVIEW 18 of 27 
 
with increased IL-1 and caspase-1 [90]. An inhibitor of NLRP3 is effective in a mouse model of severe 
neutrophilic asthma [91]. A novel endotype of severe asthma has been recognized from the U-
BIOPRED cohort of severe asthma that involves IL-6 receptor trans-signaling that may respond 
specifically to an IL-6 receptor antibody, such as tocilizumab [92]. Novel broad-spectrum anti-
inflammatory treatments, such as phosphodiesterase-4, JAK and IRAK-4 inhibitors may be useful in 
non-T2 inflammation [93,94]. Macrolide antibiotics are also effective in reducing exacerbations of 
non-T2 asthma [95,96]. The potential for antibiotic resistance is leading to a search for non-antibiotic 
macrolides that retain anti-inflammatory effects. For paucigranulocytic patients, anti-inflammatory 
treatments are not indicated, but they may benefit from adding long-acting muscarinic antagonists 
[67]; highly selected patients may benefit from bronchial thermoplasty and targeted lung 
denervation. 
 
Figure 3. Inflammatory pathways of severe asthma and potential targets of biologic drugs. 
6.6. Non Pharmacological Treatments 
The most recent edition of the GINA guidelines [6] includes bronchial thermoplasty (BT) as a 
non-pharmacological, selective treatment of severe asthma [97]. BT delivers controlled thermal 
energy to the airway wall through a dedicated catheter during a series of bronchoscopy procedures 
that result in a prolonged reduction in ASM mass, thus ameliorating symptoms of asthma. Since the 
first randomized controlled trial of BT in asthma, the Asthma Intervention Research (AIR) study’s 
[98], which showed improvements in asthma-related quality of life and reduction in the frequency of 
exacerbations following treatment with BT, large randomized clinical trials with longer-term follow-
up have supported the beneficial effect of the procedure [99–100], which has been then confirmed in 
real-life settings [101]. Many unanswered questions with regard to long-term maintenance of efficacy 
and need for expertise require that the procedure is used in selected patients, in dedicated centers.  
Pulmonary rehabilitation (PR) is a comprehensive intervention which includes exercise training, 
education and behavior change, designed to improve the physical and psychological condition of 
people with chronic respiratory disease and to promote the long-term adherence of health-enhancing 
behaviors [102]. The main goal is to impact dyspnea/fatigue and chronic respiratory symptoms. A 
recent study showed that in severe asthmatics, inspiratory capacity (IC) significantly drops during 
Figure 3. Inflammatory pathways of severe asthma and potential targets of biologic drugs.
6.6. Non Pharmacological Treatments
The most recent edition of the GINA guidelines [5] includes bronchial thermoplasty (BT) as a
non-phar acological, selective treatment of severe asthma [97]. BT delivers controlled thermal energy
to the ai w y wall through a dedicated catheter during a series of bronchoscopy p cedures that
result in a prolonged reduction in ASM mass, thus ameliorating symptoms of asthma. Since the fi st
randomized controlled trial of BT in asthma, the Asthma Inte ve tion Research (AIR) study’s [98],
J. Clin. Med. 2020, 9, 2397 19 of 27
which showed improvements in asthma-related quality of life and reduction in the frequency of
exacerbations following treatment with BT, large randomized clinical trials with longer-term follow-up
have supported the beneficial effect of the procedure [99,100], which has been then confirmed in
real-life settings [101]. Many unanswered questions with regard to long-term maintenance of efficacy
and need for expertise require that the procedure is used in selected patients, in dedicated centers.
Pulmonary rehabilitation (PR) is a comprehensive intervention which includes exercise training,
education and behavior change, designed to improve the physical and psychological condition of
people with chronic respiratory disease and to promote the long-term adherence of health-enhancing
behaviors [102]. The main goal is to impact dyspnea/fatigue and chronic respiratory symptoms. A
recent study showed that in severe asthmatics, inspiratory capacity (IC) significantly drops during
the 6MWT to the same extent as COPD subjects with a similar degree of lung impairment, indicating
the development of dynamic hyperinflation [103]. Contrary to COPD, the occurrence of dynamic
hyperinflation in asthmatic subjects does not seem to be associated with changes in dyspnea perception.
These differences should be taken into account in rehabilitation settings to personalize treatment. A
home-based PR program can be offered to many patients and can significantly improve all respiratory
function parameters [104]. Completion of PR by a population with asthma results in improvements
in exercise tolerance, weight loss, depression and quality of life [105]. Depression is a risk factor for
non-implementation of PR in patients with asthma. Improvement in asthma control is greater in patients
with uncontrolled asthma than in patients with partially controlled asthma after PR [106]. Therefore,
patients with uncontrolled asthma should be given opportunities to benefit from PR programs.
Lung transplantation (LT) can be considered another non-pharmacological approach to severe
asthmatic patients. Potential candidates are patients with fixed obstruction secondary to remodeling;
however, recent biological therapies have changed the natural history of functional impairment. In
fact, the recent literature on the topic is poor and consists of case reports or limited asthma patient
series [107–109]. Interestingly, it has been reported that non-asthmatic recipients of asthmatic lungs
may develop asthma after transplantation. On the other hand, the asthmatic recipients of normal
lungs did not develop asthma up to three years after transplantation. Selection criteria as well as
contraindications can be assimilated to those for COPD patients.
7. Severe Asthma in Acute or Difficult to Treat Settings
7.1. Acute Settings
Patients at increased risk of asthma-related death should be identified to prevent a flare-up (or
exacerbation). Risk factors include hospitalization or emergency care for asthma in the last 12 months,
any history of near-fatal asthma requiring intubation and ventilation, not currently using ICS, or poor
adherence with ICS, currently using or recently stopped using OCS, over-use of SABAs (especially if
more than one canister/month), lack of a written asthma action plan, history of psychiatric disease or
psychosocial problems, and confirmed food allergy. The current optimal pharmacological management
of asthma flare-ups is simple and straightforward, including SABA, inhaled ipratroprium bromide,
oxygen supplementation to maintain SpO2 between 93% and 95% in adults and 94% and 98% in
children, oral and IV corticosteroids, and IV magnesium. Indeed, other pharmacological approaches
sometimes used in the clinical practice [110–112] did not show to be more effective than the standard
treatment. The same was apparent for intravenous aminophylline which did not demonstrate any
additional bronchodilation compared with standard care with beta-agonists with significant adverse
effects [113]. Moreover, the existing evidence does not provide support for the administration of
helium–oxygen mixtures to all emergency department patients with asthma flare-up, with some
evidence of certain beneficial effects in patients with more severe obstruction [114]. Very limited and
sometimes anecdotic data are present for general anesthesia drugs, or propofol and ketamine [115].
Finally, the recent ERS document on NIV, given the uncertainty of evidence, was unable to offer a
recommendation of the use of NIV for acute respiratory failure due to asthma [116].
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7.2. Pregnancy
Asthma is the most common chronic medical condition reported during pregnancy and its
prevalence in the population has increased in recent decades, representing a significant public health
issue. Maternal asthma is associated with an increased risk of adverse perinatal outcomes [117]
such as pre-term birth, low birth weight, small for gestational age infants, perinatal mortality and
pre-eclampsia. Studies have reported a relationship between increased asthma severity, decreased
asthma control or asthma exacerbation and increased perinatal complications [118]. Due to several
mechanisms (i.e., maternal hormones, beta-adrenoreceptor responsiveness, fetal sex, altered immune
function, physiological respiratory changes), most women with asthma experience an unpredictable
change in asthma control while pregnant. Up to 45% of pregnant women with asthma have moderate or
severe exacerbations requiring medical intervention during pregnancy and approximately 6% of them
are hospitalized with a severe asthma flare-up [119]. The risk of asthma exacerbation during pregnancy
is a function of asthma severity [120], and correlates with non-adherence to ICS. In fact, despite data
indicating the safety of asthma medications during pregnancy, asthma remains undertreated in pregnant
women and at least one-third of patients are non-adherent to inhaled therapy. In addition, changes in
the maternal cell-mediated immunity during pregnancy may make pregnant women more susceptible
to viral infections, leading to exacerbations. International guidelines provide the recommendations
for successful clinical management of asthma in pregnancy. Optimizing asthma management in
pregnancy is pivotal to protect the health of both mother and fetus. Thus, maintaining fetal oxygenation
by preventing maternal hypoxia is the goal of treatment. With this aim, GINA recommendations
highlight the importance to aggressively treat acute exacerbations during pregnancy with SABA,
oxygen supplementation and early administration of systemic corticosteroids. Preconception care,
regular review of asthma every 4–6 weeks, stepwise approach, identification and management of
comorbidities are also recommended.
There is good evidence regarding the safety of the major drugs classes used to treat asthma
during pregnancy, including ICS, especially for budesonide, and β2-agonists. A UK population-based
study [121] evaluated the effect of maternal use on congenital malformations. Authors found that
gestational exposure to commonly used asthma medications was safe overall, although a teratogenic
risk of cromones could not be excluded. The Xolair Pregnancy Registry (EXPECT) evaluated the safety
of omalizumab in pregnant severe asthmatic women. Data collected demonstrated that the prevalence
of major congenital defects in EXPECT was not higher than those reported in the general population
with asthma [122]. In addition, omalizumab does not increase the risk of pre-term birth or small for
gestational age infants.
8. Conclusions
Severe asthma may be frustrating to treat. Patients with severe unremitting disease have the
greatest impairment of quality of life and account for a disproportionate use of health-care resources
through hospital admissions, unscheduled doctor visits and use of emergency services, thereby
accounting for a significant medical and societal burden. This is because gaps still exist in the
knowledge of the exact mechanisms underlying this condition. These proceedings of the International
Course on Severe Asthma summarize the main topics that were discussed with the aim to highlight
the many questions that remain, which, if adequately addressed, may eventually lead to improved
outcomes. Severe asthma is not a rare entity and is no longer an orphan disease. Understanding
whether severe asthma is the aggressive phenotype of a mild disease gone bad or a different disease
with particular endotypes may also help properly identify the targetable and treatable features of
all asthmas.
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